Skip to content

Assessing the Impact of COVID-19 on HMPV Incidence and Severity Among Adults

Assessing the Impact of COVID-19 on HMPV Incidence and Severity Among Adults

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06309212
Enrollment
2197
Registered
2024-03-13
Start date
2023-12-15
Completion date
2024-01-30
Last updated
2024-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Importance of Accurate Diagnosis for HPMV, The Prevalance of HMPV After COVID-19 Pandemic

Keywords

Adults, Human metapneumovirus, Post-COVID-19 era, Prevalence, Underestimated Virus

Brief summary

Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.

Detailed description

Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.

Interventions

OTHERObservation

Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay

Sponsors

Acibadem University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Adults \>18 years * Patients with acute respiratory tract infection symptoms * Patients who underwent multiplex PCR testing for respiratory viruses

Exclusion criteria

* Patients for whom no respiratory viral panel test was conducted

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of HMPV infection in adults pre- and post-COVID-19 pandemicBetween 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay

Secondary

MeasureTime frameDescription
Comparison of HMPV with other respiratory viruses in adultsBetween 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026